Also trades as: 0K10.L (LSE) · $vol 0M
MTD NYSE
Mettler-Toledo International Inc.
1W: +2.8%
1M: +10.5%
3M: +20.3%
YTD: +18.4%
1Y: +16.2%
3Y: +64.8%
5Y: +17.6%
$1,686.84
+17.21 (+1.03%)
Weekly Expected Move ±3.3%
$1557
$1613
$1669
$1724
$1780
Credit Risk of going bust: lower than 85% of companies Debt: 5.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $7.75 (down 99.5%), Mettler-Toledo International Inc. would be worth roughly what it owes.
Total debt $2.11B against a stock market value of $33.45B.
Distance to default 11.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.09B (short-term plus half of long-term), stock volatility 31.9%; Altman Z'' 10.97. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $7.75 (down 99.5%), Mettler-Toledo International Inc. would be worth roughly what it owes.
Total debt $2.11B against a stock market value of $33.45B.
Distance to default 11.15 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.09B (short-term plus half of long-term), stock volatility 31.9%; Altman Z'' 10.97. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#9
of 91
Medical - Diagnostics & Research
Technical Signal Map
19 Bullish
0 Neutral
1 Bearish
MTD
$33B
Mettler-Toledo International Inc.
BULLISH
+91
LH
$27B
Labcorp Holdings Inc.
BULLISH
+100
MEDP
$19B
Medpace Holdings, Inc.
BULLISH
+100
CRL
$17B
Charles River Laboratories International, Inc.
BULLISH
+100
QGEN
$10B
Qiagen N.V.
BULLISH
+100
DHR
$162B
Danaher Corporation
BULLISH
+91
ICLR
$14B
ICON Public Limited Company
BULLISH
+91
IDXX
$44B
IDEXX Laboratories, Inc.
BULLISH
+87
TMO
$249B
Thermo Fisher Scientific Inc.
BULLISH
+82
NTRA
$58B
Natera, Inc.
BULLISH
+69
IQV
$46B
IQVIA Holdings Inc.
BULLISH
+66
WAT
$45B
Waters Corporation
BULLISH
+66
DGX
$27B
Quest Diagnostics Incorporated
BULLISH
+59
RVTY
$18B
Revvity, Inc.
BULLISH
+58
BMXXY
$12B
bioMérieux S.A.
BULLISH
+50
ERFSF
$17B
Eurofins Scientific SE
BULLISH
+41
ILMN
$41B
Illumina, Inc.
LEAN BULL
+27
A
$49B
Agilent Technologies, Inc.
LEAN BULL
+24
GH
$23B
Guardant Health, Inc.
LEAN BULL
+10
WUXAY
$68B
WuXi AppTec Co., Ltd.
BEARISH
-75
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| LH Labcorp Holdings Inc. | $27B | 26.9 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 17.4 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 13.4 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 87.0 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 2.1 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| ICLR ICON Public Limited Company | $14B | 42.7 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.1 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -10.7 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| NTRA Natera, Inc. | $58B | -297.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 107.6 |
| IQV IQVIA Holdings Inc. | $46B | 33.0 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 24.4 |
| WAT Waters Corporation | $45B | 114.0 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 28.2 |
| DGX Quest Diagnostics Incorporated | $27B | 23.6 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 32.6 |
| RVTY Revvity, Inc. | $18B | 76.0 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 64.4 |
| BMXXY bioMérieux S.A. | $12B | 22.6 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 33.0 |
| ILMN Illumina, Inc. | $41B | 51.2 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 171.1 |
| A Agilent Technologies, Inc. | $49B | 34.6 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.3 |
| GH Guardant Health, Inc. | $23B | -49.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 149.8 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 85.4 |
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.7 |
| CNC Centene Corp. | $35B | 23.8 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 98.1 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.0 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 28.6 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.2 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -6.8 |
| ZTS Zoetis Inc. | $33B | 13.0 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -44.5 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| ALC Alcon Inc. | $34B | 53.5 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.2 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| RSMDF ResMed Inc. | $36B | 23.9 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -8.5 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MDLN Medline Inc. | $30B | 38.5 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 10.6 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| MTD Mettler-Toledo International Inc. | $33B | 37.5 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 16.2 |
| MDT Medtronic Plc | $122B | 23.0 | 10.7 | 7.8 | 15.1 | 9.8 | 9 | BULLISH | 4.0 |
| LZAGY Lonza Group AG | $54B | -409.1 | 13.5 | 10.5 | 17.5 | -9.7 | 8 | BULLISH | 6.2 |
| ORINY Orion Oyj | $30B | 23.1 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 46.8 |
| RPRX Royalty Pharma plc | $28B | 26.9 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BULLISH | 76.7 |
| LH Labcorp Holdings Inc. | $27B | 26.9 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BULLISH | 17.4 |
| ZBH Zimmer Biomet Holdings, Inc. | $19B | 23.2 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BULLISH | -5.5 |
| MEDP Medpace Holdings, Inc. | $19B | 36.7 | 117.9 | 1953.7 | 19.2 | 20.4 | 9 | BULLISH | 13.4 |
| CRL Charles River Laboratories International, Inc. | $17B | -73.3 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | BULLISH | 87.0 |
| HALO Halozyme Therapeutics, Inc. | $14B | 36.0 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | BULLISH | 91.4 |
| QGEN Qiagen N.V. | $10B | 25.8 | 11.9 | 11.2 | 19.3 | 3.0 | 8 | BULLISH | 2.1 |
| ABBV AbbVie Inc. | $505B | 80.5 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.7 |
| PFE Pfizer Inc. | $171B | 39.3 | 5.0 | 11.3 | -1.6 | -0.2 | 7 | BULLISH | 22.9 |
| DHR Danaher Corporation | $162B | 37.9 | 8.3 | 6.3 | 18.8 | 5.5 | 7 | BULLISH | 5.4 |
| CVS CVS Health Corp. | $120B | 24.2 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BULLISH | 14.1 |
| MCK McKesson Corporation | $117B | 26.2 | -148.0 | 237.7 | 0.6 | 8.8 | 8 | BULLISH | 25.3 |
| ELV Elevance Health Inc. | $95B | 18.2 | 11.6 | 16.2 | 2.7 | 3.6 | 7 | BULLISH | 25.2 |
| REGN Regeneron Pharmaceuticals, Inc. | $83B | 19.4 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BULLISH | 40.5 |
| CI Cigna Corporation | $81B | 12.5 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BULLISH | 0.9 |
| TKPHF Takeda Pharmaceutical Company Limited | $66B | 56.1 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 41.9 |
| CAH Cardinal Health, Inc. | $58B | 34.3 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BULLISH | 59.6 |
| BDX Becton, Dickinson and Company | $54B | 58.7 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BULLISH | 5.9 |
| SDZNY Sandoz Group AG | $42B | 66.7 | 7.2 | 10.1 | 1.9 | 29.1 | 6 | BULLISH | 60.0 |
| OTSKY Otsuka Holdings Co., Ltd. | $42B | 16.0 | 13.8 | 12.2 | 16.7 | 10.9 | 8 | BULLISH | 45.1 |
| ONC BeOne Medicines AG | $40B | 25.2 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | BULLISH | 19.6 |
| CNC Centene Corp. | $35B | 23.8 | 6.8 | 6.4 | -0.1 | 4.8 | 8 | BULLISH | 98.1 |
| WST West Pharmaceutical Services, Inc. | $28B | 50.0 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 28.6 |
| EXEL Exelixis, Inc. | $16B | 19.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 71.1 |
| ICLR ICON Public Limited Company | $14B | 42.7 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BULLISH | 2.1 |
| PMCUF Pro Medicus Limited | $13B | 78.1 | 75.0 | 68.1 | 68.7 | 22.8 | 7 | BULLISH | -30.9 |
| AVTR Avantor, Inc. | $12B | -20.5 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | BULLISH | 11.8 |
| GKOS Glaukos Corporation | $11B | -56.6 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BULLISH | 137.1 |
| HCA HCA Healthcare, Inc. | $102B | 54.8 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | BULLISH | 5.7 |
| IDXX IDEXX Laboratories, Inc. | $44B | 39.5 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BULLISH | -10.7 |
| GEHC GE HealthCare Technologies Inc. | $32B | 20.2 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BULLISH | -6.8 |
| CLPBY Coloplast A/S | $17B | 38.5 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BULLISH | -21.7 |
| ASND Ascendis Pharma A/S | $15B | 18.1 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BULLISH | 22.0 |
| PEN Penumbra, Inc. | $13B | 79.4 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BULLISH | 28.3 |
| ABT Abbott Laboratories | $179B | 38.3 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BULLISH | -17.0 |
| ISRG Intuitive Surgical, Inc. | $160B | 53.8 | 18.0 | 22.6 | 17.1 | 20.5 | 7 | BULLISH | -18.1 |
| SYK Stryker Corporation | $118B | 30.8 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BULLISH | -20.0 |
| SNY Sanofi | $100B | 23.0 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BULLISH | -15.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $74B | 23.3 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BULLISH | 1.2 |
| BSX Boston Scientific Corporation | $66B | 18.1 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BULLISH | -55.5 |
| UTHR United Therapeutics Corporation | $25B | 19.3 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 39.1 |
| PODD Insulet Corp. | $10B | 27.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BULLISH | -53.9 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.2 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 19.8 |
| WILYY Demant A/S | $12B | 46.7 | 15.9 | 10.9 | 9.1 | 10.6 | 5 | BULLISH | 47.3 |
| HLN Haleon plc | $45B | 20.7 | 10.1 | 8.4 | 13.6 | 1.3 | 8 | BULLISH | 8.9 |
| ZTS Zoetis Inc. | $33B | 13.0 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BULLISH | -44.5 |
| PHG Koninklijke Philips N.V. | $26B | 20.3 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BULLISH | -8.4 |
| SNN Smith & Nephew plc | $13B | 19.8 | 11.8 | 9.9 | 9.8 | 5.3 | 7 | BULLISH | -14.2 |
| COO The Cooper Companies, Inc. | $12B | 20.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | BULLISH | -17.9 |
| RHHBF Roche Holding AG | $393B | 25.8 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 16.8 |
| ESLOF EssilorLuxottica S.A. | $94B | 33.2 | 6.5 | 5.2 | 10.6 | 7.4 | 6 | BULLISH | -44.7 |
| SOAGY Sartorius AG ADR | $92B | 90.9 | 7.7 | 6.6 | 7.1 | 4.3 | 7 | BULLISH | 18.0 |
| EW Edwards Lifesciences Corporation | $51B | 51.7 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BULLISH | 18.3 |
| BIIB Biogen Inc. | $37B | 44.2 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | BULLISH | 68.1 |
| TRUMY Terumo Corporation | $22B | 21.5 | 11.0 | 9.6 | 22.6 | 15.6 | 5 | BULLISH | -8.5 |
| ALGN Align Technology, Inc. | $11B | 26.3 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BULLISH | 12.0 |
| NTRA Natera, Inc. | $58B | -297.1 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 107.6 |
| LLY Eli Lilly and Company | $1.2T | 43.0 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 56.0 |
| AMGN Amgen Inc. | $237B | 27.4 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 56.0 |
| MKGAF Merck KGaA | $70B | 26.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | BULLISH | 24.1 |
| COR Cencora, Inc. | $63B | 24.2 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BULLISH | 0.7 |
| IQV IQVIA Holdings Inc. | $46B | 33.0 | 21.7 | 33.3 | 7.9 | 8.8 | 9 | BULLISH | 24.4 |
| WAT Waters Corporation | $45B | 114.0 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 28.2 |
| GNMSF Genmab A/S | $28B | 34.9 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 50.6 |
| SONVF Sonova Holding AG | $20B | 38.9 | 20.4 | 17.2 | 19.7 | -7.1 | 6 | BULLISH | 22.9 |
| BAX Baxter International Inc. | $13B | -12.2 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BULLISH | 10.2 |
| UCBJY UCB S.A. | $58B | 23.3 | 20.7 | 16.4 | 26.0 | 25.3 | 6 | BULLISH | 5.3 |
| ALC Alcon Inc. | $34B | 53.5 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BULLISH | -8.2 |
| STE STERIS plc | $23B | 27.9 | 11.4 | 9.7 | 13.4 | 8.4 | 8 | BULLISH | -4.6 |
| GSK GSK plc | $102B | 16.0 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BULLISH | 13.2 |
| SEMHF Siemens Healthineers AG | $53B | 21.2 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BULLISH | -17.7 |
| DGX Quest Diagnostics Incorporated | $27B | 23.6 | 15.2 | 10.2 | 10.1 | 9.1 | 8 | BULLISH | 32.6 |
| SAUHY Straumann Holding AG | $19B | 41.8 | 17.3 | 21.7 | 18.1 | 3.0 | 6 | BULLISH | 5.1 |
| NBIX Neurocrine Biosciences, Inc. | $15B | 20.6 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BULLISH | 1.5 |
| GMED Globus Medical, Inc. | $11B | 20.2 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BULLISH | 30.2 |
| CSLLY CSL Limited | $134B | -26.2 | -15.2 | 13.1 | -40.2 | 1.7 | 4 | BULLISH | -1.5 |
| RVTY Revvity, Inc. | $18B | 76.0 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 64.4 |
| TECH Bio-Techne Corporation | $11B | 62.1 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | BULLISH | 10.2 |
| MOH Molina Healthcare, Inc. | $11B | -329.7 | -1.2 | -44.2 | 0.4 | -2.1 | 5 | BULLISH | 27.3 |
| IPSEY Ipsen S.A. | $58B | 24.4 | 11.5 | 16.3 | 18.2 | 8.0 | 6 | BULLISH | 25.4 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BULLISH | 3.0 |
| GILD Gilead Sciences, Inc. | $193B | -60.6 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BULLISH | 32.3 |
| DSNKY Daiichi Sankyo Company, Limited | $33B | 19.6 | 15.1 | 12.5 | 11.9 | 17.4 | 5 | BULLISH | -33.2 |
| ROIV Roivant Sciences Ltd. | $26B | -95.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BULLISH | 99.0 |
| VTRS Viatris Inc. | $21B | -51.7 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 79.5 |
| BMXXY bioMérieux S.A. | $12B | 22.6 | 11.2 | 8.9 | 11.5 | -3.5 | 7 | BULLISH | -28.0 |
| DVA DaVita Inc. | $12B | 15.7 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BULLISH | 43.8 |
| UHS Universal Health Services, Inc. | $11B | 7.2 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | BULLISH | -10.8 |
| RDY Dr. Reddy's Laboratories Limited | $11B | 39.0 | 7.5 | 6.0 | 10.7 | -3.1 | 4 | BULLISH | -5.9 |
| HUM Humana Inc. | $51B | 39.2 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | BULLISH | 43.1 |
| RCDTF Recordati Industria Chimica e Farmaceutica S.p.A. | $12B | 21.8 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| JNJ Johnson & Johnson | $636B | 40.5 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 39.2 |
| FSNUY Fresenius SE & Co. KGaA | $117B | 16.8 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BULLISH | -18.2 |
| ENSG The Ensign Group, Inc. | $10B | 26.2 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BULLISH | -4.6 |
| THC Tenet Healthcare Corporation | $22B | 9.8 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BULLISH | 30.0 |
| UNH UnitedHealth Group Incorporated | $375B | 23.5 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.7 |
| ERFSF Eurofins Scientific SE | $17B | 28.5 | 12.8 | 4.6 | 8.2 | 3.3 | 6 | BULLISH | 33.0 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $16B | 60.2 | 23.3 | 27.3 | 20.6 | 5.0 | 6 | BULLISH | 45.1 |
| EHC Encompass Health Corporation | $12B | 19.5 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BULLISH | -1.8 |
| VRTX Vertex Pharmaceuticals Incorporated | $133B | 29.7 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BULLISH | 22.4 |
| SGIOY Shionogi & Co., Ltd. | $16B | 9.8 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BULLISH | 20.9 |
| RGEN Repligen Corporation | $11B | -823.9 | -0.6 | -1.4 | -18.4 | 13.8 | 4 | BULLISH | 9.0 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 64.8 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -1.8 |
| ALPMF Astellas Pharma Inc. | $30B | 12.4 | 21.4 | 16.9 | 22.1 | 17.3 | 7 | BULLISH | 65.7 |
| ILMN Illumina, Inc. | $41B | 51.2 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | LEAN BULL | 171.1 |
| BBIO BridgeBio Pharma, Inc. | $13B | -19.2 | 32.4 | 57.9 | -62.5 | 202.4 | 4 | LEAN BULL | 26.6 |
| A Agilent Technologies, Inc. | $49B | 34.6 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | LEAN BULL | 19.3 |
| HOCPY HOYA Corporation | $56B | 33.4 | 27.3 | 46.1 | 25.7 | 14.2 | 6 | LEAN BULL | 10.1 |
| BMY Bristol-Myers Squibb Company | $126B | 13.5 | 46.7 | 17.8 | 25.6 | 3.1 | 8 | LEAN BULL | 46.8 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 64.1 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | LEAN BULL | 110.1 |
| BIOVF Swedish Orphan Biovitrum AB | $16B | 115.7 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | LEAN BULL | 37.3 |
| GH Guardant Health, Inc. | $23B | -49.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | LEAN BULL | 149.8 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 12.2 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | NEUTRAL | -15.4 |
| AAVXF Abivax S.A. | $12B | -16.7 | -221.8 | 440.6 | — | -133.5 | 4 | NEUTRAL | 57.0 |
| JDHIY JD Health International Inc. | $16B | 16.4 | 10.3 | 31.0 | 8.4 | 19.6 | 6 | NEUTRAL | -43.9 |
| CHJTF CSPC Pharmaceutical Group Limited | $14B | 10.3 | 20.7 | 36.7 | 32.8 | 88.1 | 6 | NEUTRAL | 13.3 |
| NONOF Novo Nordisk A/S | $172B | 9.9 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | NEUTRAL | -28.1 |
| IHHHF IHH Healthcare Berhad | $15B | 30.9 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | NEUTRAL | 43.7 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 75.8 |
| MRNA Moderna, Inc. | $80B | -23.4 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | LEAN BEAR | 681.3 |
| SUVPF Sartorius AG | $19B | 90.9 | 7.7 | 6.7 | 7.1 | 3.6 | 7 | LEAN BEAR | 8.9 |
| RSMDF ResMed Inc. | $36B | 23.9 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | LEAN BEAR | -8.5 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 41.0 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | LEAN BEAR | 70.4 |
| ELAN Elanco Animal Health Incorporated | $11B | -55.9 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 5.5 |
| ARGX argenx SE | $55B | 31.3 | 26.0 | 50.1 | 29.8 | 162.5 | 7 | BEARISH | 7.0 |
| WXIBF WuXi Biologics (Cayman) Inc. | $26B | 31.4 | 10.6 | 16.0 | 20.7 | 16.0 | 9 | BEARISH | 23.1 |
| BAYRY Bayer AG | $48B | -25.8 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 59.4 |
| INCY Incyte Corporation | $23B | 14.1 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 26.9 |
| SOLV Solventum Corporation | $15B | 10.1 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 18.8 |
| IVBXF Innovent Biologics, Inc. | $20B | 97.0 | 6.9 | 67.2 | 14.5 | 35.4 | 6 | BEARISH | -5.6 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 146.9 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 2.2 |
| OCPNF Olympus Corporation | $12B | 24.6 | 10.6 | 12.7 | 7.9 | 7.8 | 5 | BEARISH | -9.8 |
| ALNY Alnylam Pharmaceuticals, Inc. | $30B | 37.1 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -50.9 |
| MDLN Medline Inc. | $30B | 38.5 | 3.2 | 4.4 | 0.8 | — | 4 | BEARISH | — |
| RVMDW Revolution Medicines, Inc. Warrant | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 2279.1 |
| MRK Merck & Co., Inc. | $358B | 112.0 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 62.7 |
| WUXAY WuXi AppTec Co., Ltd. | $68B | 15.4 | 30.2 | 35.4 | 39.1 | 25.0 | 8 | BEARISH | 85.4 |
| TEM Tempus AI, Inc. | $12B | -48.0 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BEARISH | -22.8 |
| RVMD Revolution Medicines, Inc. | $40B | -20.6 | -79.1 | 186.4 | — | — | 1 | BEARISH | 243.7 |
| DXCM DexCom, Inc. | $29B | 30.4 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | BEARISH | 10.6 |
| BNTX BioNTech SE | $22B | -11.4 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -17.1 |
| JAZZ Jazz Pharmaceuticals plc | $14B | 13.6 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 48.9 |
| MDGL Madrigal Pharmaceuticals, Inc. | $10B | -34.2 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 3.3 |
| INSM Insmed Incorporated | $20B | -23.1 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -41.7 |
| GIKLY Grifols, S.A. | $15B | 15.9 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | BEARISH | -19.0 |
| SMMT Summit Therapeutics Inc. | $12B | -13.2 | -192.5 | 1714.4 | — | — | 3 | BEARISH | -22.7 |
| SBMFF Sino Biopharmaceutical Limited | $12B | 30.4 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BEARISH | -28.2 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
MTD vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F